




# Optimizing Evidence-Based Treatment Planning With Multikinase Inhibition in mCRC and uHCC

Saturday, 20 October 2018  
18.30 - 20.00

Hall A1 - Room 16  
Messe Munich  
Munich, Germany



## FACULTY

**Axel Grothey, MD (Chair)**  
Sarah Cannon Cancer Center  
Nashville, USA

**Michel Ducreux, MD, PhD**  
Institut Gustave Roussy  
Villejuif, France

**Heinz-Josef Lenz, MD**  
University of Southern California  
Los Angeles, USA

**Chris Verslype, MD, PhD**  
University Hospital Leuven  
Leuven, Belgium

## AGENDA

- 18.30 - 18.35 **Opening Remarks**  
Axel Grothey, MD
- 18.35 - 18.50 **Mechanistic Insights Into Therapeutic Multikinase Inhibition**  
Heinz-Josef Lenz, MD
- 18.50 - 19.10 **Evidence-Based Treatment Planning With Multikinase Inhibitors in 3L mCRC**  
Axel Grothey, MD
- 19.10 - 19.30 **Real-World Evidence Value in Treatment Planning in 3L mCRC**  
Michel Ducreux, MD, PhD
- 19.30 - 19.50 **Sequencing in HCC: Establishing a Reliable Standard of Care to Improve Survival**  
Chris Verslype, MD, PhD
- 19.50 - 20.00 **Moderated Discussion and Meeting Close**  
Axel Grothey, MD

G.MKT.SM.ON.08.2018.2588

